Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Share-based Compensation (2024 - 2025)

Historic Share-based Compensation for Kura Oncology (KURA) over the last 2 years, with Q3 2025 value amounting to $11.0 million.

  • Kura Oncology's Share-based Compensation rose 3172.75% to $11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $34.4 million, marking a year-over-year change of. This contributed to the annual value of $33.9 million for FY2024, which is 2070.72% up from last year.
  • Latest data reveals that Kura Oncology reported Share-based Compensation of $11.0 million as of Q3 2025, which was up 3172.75% from $6.9 million recorded in Q2 2025.
  • Kura Oncology's 5-year Share-based Compensation high stood at $11.0 million for Q3 2025, and its period low was $6.9 million during Q2 2025.